•
Dec 31, 2023

DexCom Q4 2023 Earnings Report

Dexcom's revenue grew, driven by volume and new customer additions, with significant increases in operating and net income.

Key Takeaways

Dexcom reported a strong fourth quarter in 2023, with revenue increasing by 27% year-over-year to $1.03 billion. GAAP operating income increased significantly, and net income saw a substantial rise. The company also provided annual guidance for 2024.

Revenue grew 27% year-over-year to $1.03 billion.

U.S. and International revenue both grew by 27%.

GAAP operating income increased by 560 basis points compared to Q4 2022.

Submitted Stelo, Dexcom’s new glucose sensor for people with type 2 diabetes who do not use insulin, to the FDA for review.

Total Revenue
$1.03B
Previous year: $815M
+26.9%
EPS
$0.5
Previous year: $0.34
+47.1%
Gross margin
63.5%
Previous year: 66.4%
-4.4%
Operating margin
21%
Previous year: 15.4%
+36.4%
Gross Profit
$657M
Previous year: $541M
+21.3%
Cash and Equivalents
$566M
Previous year: $642M
-11.8%
Free Cash Flow
$81.1M
Previous year: $69M
+17.5%
Total Assets
$6.26B
Previous year: $5.39B
+16.2%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

The company is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin, and establishing Adjusted EBITDA Margin guidance.

Positive Outlook

  • Revenue of approximately $4.15 - 4.35 billion (16 - 21% organic growth3)
  • Non-GAAP Gross Profit Margin of approximately 63 - 64%
  • Non-GAAP Operating Margin of approximately 20%
  • Adjusted EBITDA Margin of approximately 29%

Revenue & Expenses

Visualization of income flow from segment revenue to net income